www.bioniche.com

Positive results is around the corner..Dont miss the train !!FDA approval for Econiche (E.coli Vaccine) & Urocidin (Bladder Cancer) Phase III Data in3Q 2010 !! .Please do your own Homework.Bioniche Has The Potential To Become The Next 10-Bagger .

Bioniche Life Sciences (BNC.TO) Market Cap: 74,6 Mil $Cash: 22 Mil $Price: 1,03 $

Dundee Sec with Buy-Rating (June 2010)....Bioniche has three businesses with diversified risk/reward profiles:Animal Health, whichis expected to generate around $28 million in salesin fiscal 2010; Human Health, withPhase 3 results expected in mid-2010from lead product, Urocidin, testing for bladdercancer; and FoodSafety, with Canadian approval and a conditional license pending intheU.S. of a vaccine for reducing E. coli 0157 in cattle feces, and apipeline of othervaccines.

Mr. Martin points out that Urocidin provides the “biggest upsidepotential” forBioniche investors. His initial diligence suggests thatUrocidin has a “relatively highoverall probability of approval,” eventhough the first of two planned Phase 3 trials hasa moderate level ofrisk, as the refractory patients enrolled in the trial area“tougher-to-treat” population than was enrolled in the Phase 2 trial, hesays.Mitigating the risk somewhat is the 20% “complete response” hurdlerequired for Phase3. That compares with the company’s Phase 2 results,where patients achieved a 46.4% CRrate at 26 weeks in a population thatwas mainly relapsed but also included a few patientsbeing treated forthe first time.

A second planned Phase 3 trial will test Urocidin head-to-head againstthe current standardof care, baccilus Calmette-Guerin (BCG) infirst-line treatment, “where we expect Urocidin to demonstrate betterefficacy, based on prior data, and superior safety andtolerability,” hepredicts.In 2009, Bioniche licensed Urocidin’s U.S. commercial rights to EndoPharmaceuticals.Based on incidence of bladder cancer and possiblepricing, he figures the global marketopportunity for Urocidin in therefractory population could be $800 million.

If the secondPhase 3 trialexpands the Urocidin label to first-line treatment, the marketopportunitycould grow to an estimated $2 billion.“Twenty-five percent penetration of this market would represent $500million in annualsales and an estimated $112.5 million in gross profitfor Bioniche,” Mr. Martin says .